Building better cell therapies begins here

Advances in cell therapy development have helped provide essential proof points for cell therapy, but the cost-per-dose and time required for product development are often too high to deliver on cell therapy’s true promise.  

At Cellistic, we have fully invested in the team, processes, and infrastructure required to fulfill the “one-batch-to-many-patients” promise of iPSC-based allogeneic cell therapy. It all happens through our Pulse™ + Echo™ Platforms, the world’s first off-the-shelf, pre-built cell line development and manufacturing platforms.

Group 32
Cellistic Platform Graphic

Tuned in a way that lets you plug in wherever you are in the process, Pulse™ + Echo™ provide product-centric support from candidate gene editing through to clinical GMP product supply of your cell therapy.

_PH-Pulse-Mark

Cell line development that enables you to advance toward your banked cell.

_PH-Echo-Mark

Cell therapy manufacturing that efficiently scales banked iPSCs to drug product.

Seize a powerful advantage

 

Pulse™ + Echo™ have been designed and engineered to clear a path for cell therapy innovators intent to benefit on what iPSC-based allogeneic cell therapy can uniquely offer.

_CELL-24-005-Website-Refresh-graphics-PE-overview-icon-1 1

Reduce Risk

With over +100 people focused in iPSC and a proven track record in delivering iPSC, your project is in safe hands

_CELL-24-005-Website-Refresh-graphics-PE-overview-icon-2 4

Save Time

You can skip time-consuming steps, with process development work already complete for key immunotherapy cell types

_CELL-24-005-Website-Refresh-graphics-PE-overview-icon-3 1

Limit Costs

Since every day in development has a cost attached, reducing your timeline to clinical drives bottom-line benefits 

Seize a powerful advantage

 

Pulse + Echo have been designed and engineered to clear a path for cell therapy innovators intent to benefit on what iPSC-based allogeneic cell therapy can uniquely offer.

Layer 1 (4)
Reduce Risk

With over +100 people focused in iPSC and a proven track record in delivering iPSC, your project is in safe hands

Time
Save Time

You can skip time-consuming steps, with process development work already complete for key immunotherapy cell types

Limit Costs
Limit Costs

Since every day in development has a cost attached, reducing your timeline to clinical drives bottom-line benefits 

Let’s Advance Your Therapy Together

 

Pulse™ + Echo™ have been specifically built to align with cell therapy innovators’ most pressing scientific and business needs. To find out if they’re a good fit for what’s shaping your approach to drug development and manufacturing, let’s start with a conversation.